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Highlights 
 A novel blood-specific differentially methylated locus (EFS) was investigated. 
 Most CpGs, especially CpG4, was found highly methylated in whole blood. 
 EFS methylation has the potential to differentiate between whole and menstrual blood. 
 The designed bisulfite pyrosequencing assay is both accurate and reproducible. 
 The method’s applicability to casework was demonstrated via aged and mixed stains. 
Abstract 
DNA methylation patterns have the ability to reveal the activities of genes within a certain 
tissue at a particular time point. Tissue-specific DNA methylation patterns have been 
previously investigated for their applicability in the identification of forensically relevant body 
fluids, however there is still a lack in robust markers. While following a genome-wide scale 
investigation has a great potential to reveal useful tissue-specific changes, a gene-targeted 
approach can also lead to significant outcomes, especially in genomic locations not included 
in the genome-wide experiments. In this study, the potential of the candidate embryonal Fyn-
associated substrate (EFS) gene for the positive identification of whole blood was 
investigated. For this purpose, the methylation profile of a selected genomic region 
containing a total of 10 CpG sites was analysed in 124 individuals via bisulfite 
pyrosequencing. Volunteers donated various forensically relevant tissues, including whole 
blood, saliva, seminal fluid, vaginal fluid and menstrual secretion. Whole blood showed the 
highest levels of DNA methylation (mean=0.67), while semen samples were found to be very 
low methylated (mean=0.06). The remaining tissues demonstrated partial mean methylation 
levels; more specifically, saliva – 0.43, vaginal fluid – 0.22 and menstrual blood – 0.22. One 
out of the 10 analysed CpG sites, CpG4, showed to be more robust, resulting in not only the 
highest methylation difference between blood and the rest of the tissues, but also the lowest 
inter-individual methylation difference. The proposed pyrosequencing assay was found to be 
accurate, linear and reproducible. Lastly, the method’s applicability to forensic casework was 
assessed via the analysis of very old bloodstains stored up to 18 years, blood DNA samples 
stored long-term up to 9 years, mixed stains as well as other ‘forensic-like’ samples. In the 
majority of cases the expected methylation ratios were obtained indicating a stable DNA 
methylation pattern, however caution is necessary when analysing low quantity and/or 
quality samples due to potential stochastic effects. Future validation experiments can shed 
more light into the usefulness of EFS locus as a promising blood-specific epigenetic marker. 
Keywords: forensic tissue identification; ; ; ; ; , blood, epigenetics, DNA methylation, 
bisulfite pyrosequencing, EFS gene 
  
1. Introduction 
Various cellular decisions including survival, growth and differentiation are controlled by 
particular gene expression patterns, which are further regulated by changes in the 
epigenetic state of ‘key’ genes. The possibility of quantifying the DNA methylation levels of 
specific genes is of interest in a broad range of scientific and medical disciplines. It is known 
that the epigenome acts as an interphase between the fixed genome and the dynamic 
environment, and can change according to the specific needs of a cell [1]. Therefore, DNA 
methylation patterns could reveal the activities of genes within a certain tissue at a particular 
point in time. Tissue-specific methylation patterns have been investigated either by 
analysing specific gene loci [2], entire chromosomes [3] or on a genome-wide scale [4]. 
There are numerous studies that have looked at differential methylation patterns across 
various tissues in order to identify a comprehensive genome-wide set of tissue-specific 
differentially methylated regions (tDMRs) that could play a role in cellular identity as well as 
the regulation of tissue-specific genome function [2-7]. Although epigenetics, specifically 
through the study of differentially methylated CpG sites, is a well-established approach in 
gene expression studies, from a forensic standpoint the application of epigenetic markers 
and the analysis of DNA methylation patterns is a relatively new field.  
Over the last few years there have been several studies published that attempt to utilise 
epigenetic markers in the field of forensic tissue identification [8-14]. It is evident why a DNA-
based approach for identifying the cellular origin of a tissue stain can be beneficial over 
tissue-specific mRNA typing, which has been considered as confirmatory testing for forensic 
purposes. It has the potential to not only provide a direct link to the biological material used 
in personal identification, but also benefit from DNA’s greater stability. It also has 
applicability in cold cases, where often minute stains or only DNA extracts may have been 
retained over time; however, we do acknowledge that this depends on sample availability 
and extraction method used. These studies of epigenetic markers have usually either 
validated previously reported tissue-specific markers or have attempted to discover new 
CpG sites through genome-wide methylation analysis. Although some of these techniques 
seem to be quite sensitive [15] and therefore, suitable for use in forensic specimens, marker 
specificity issues have been reported. With the exception of semen identification, which has 
been proven relatively easy to differentiate due to its distinct cellular and biochemical nature 
[16-20], finding highly robust markers for more complex biological fluids such as blood, 
menstrual blood or vaginal fluid has been particularly challenging. It is important to 
appreciate that, whereas semen mainly consists of one cell type, meaning sperm cells 
(however, in certain cases it can occasionally contain other cell types such as white blood 
cells [21]), other body fluids like blood comprise many different types of cells, each able to 
demonstrate a distinct DNA methylation profile. DNA methylation analysis has already been 
proposed as a tool for cell typing in cell therapeutic approaches. For example, Baron et al 
identified panels of cell type-specific differentially methylated gene regions, which allowed 
for accurate identification and quantification of subpopulations in cell cultures [22].  
Venous blood is of particular importance in forensic casework as it is considered the most 
common recovered biological material and there are cases where its origin can be vital to 
the outcome of a case. For example, current techniques would not normally distinguish 
venous from menstrual blood. While both would give positive reactions using presumptive 
chemical tests, even tissue-specific mRNA typing could still raise doubts about the origin, 
mainly due to the co-existence of blood peaks when menstrual blood is present [23, 24]. In 
DNA methylation-based studies in forensic identification for blood, potential markers such as 
cg06379435 [25, 26], cg08792630 [26], cg26285698 [12], cg04011671 and cg18454288 [14] 
have been identified through genome-wide methylation arrays, such as the Illumina Human 
Methylation 450K bead array. Others have focused more on a candidate gene approach in 
order to identify blood-specific differentially methylated regions, such as seen in the reported 
potentially blood-specific tDMR in the gene GAS2L1 [27]. However, it is evident that the 
discovery and identification of more forensically relevant tissue-specific CpG sites is 
necessary prior to the development of an applicable tissue-ID multiplex protocol. 
In this study, and following a literature review of potential genes that demonstrate a blood-
specific DNA methylation pattern, the embryonal Fyn-associated substrate (EFS) gene was 
selected as a likely candidate. Neumann et al analysed the methylation status of the EFS 
gene, and more specifically the region Chr14: 23,835,859-23,835,970 (GrCh37/hg19) 
including a total of 11 CpG sites, in various tissues including blood, buccal cells, sperm, 
brain and reported tissue-specific methylation patterns [28]. They found that EFS is highly 
methylated in blood, completely unmethylated in sperm and partially methylated in buccal 
cells. Therefore, this marker could be a good candidate for blood detection and the aim of 
this study was to investigate its potential and apply it to the analysis of other forensically 
relevant tissues. 
2. Material and Methods 
2.1.  Sample Collection 
Biological fluid samples used in this study were collected following full ethical approval by 
the appropriate Research Ethics Subcommittee at King’s College London (BDM RESC 
13/14-30). Full informed consent was obtained from all donors prior to sample collection. In 
total, 124 volunteers of both sexes and various ethnic backgrounds with ages ranging from 
23 to 68 years old participated in this study. Individuals had the choice to donate one or 
more body fluids/tissues including whole blood, saliva, buccal cells, seminal fluid, vaginal 
fluid and menstrual secretion. Up to 20 ml of whole blood were collected by a trained 
phlebotomist in a clean clinical environment. All other body fluid samples were collected 
either using a cotton swab or a suitable receptacle by the participants in the privacy of their 
homes. Information such as subject’s gender, geographic ancestry, and age were also 
recorded. 
2.2.  Validation samples 
For validation purposes, a set of aged stains or DNA samples were used which had been 
previously collected for research purposes. The set included five blood samples stored for 9-
18 years in the dark and at room temperature, and five blood DNA samples stored for 1-9 
years at -20oC. Using freshly collected samples, the following body fluid stains were also 
prepared: (a) mock casework blood samples including 1µl on a piece of fabric from a pair of 
denim jeans, 3µl on shirt which was then washed, 3µl on a towel and 5µl on tissue paper, (b) 
mixed stains including 1µl blood:1µl semen, and 2µl blood:1µl saliva on swabs, (c) 
artificially-degraded blood samples by exposing 1µl under UV for 0, 10, 30, 60, 90, 120 and 
240 minutes, and lastly, (d) 5µl of blood on fabric stored at various temperatures (-20oC, 
4oC, 25oC, 37oC, outdoors) for a week. All fresh stains were left at room temperature to dry 
overnight before analysis. 
2.3. DNA extraction and quantification 
DNA was isolated using the QIAamp DNA Investigator kit (QIAGEN, Hilden, Germany) using 
the appropriate protocol depending on the tissue and following the manufacturer’s 
recommendation. To assess the quantity of the resulting solution, DNA samples were 
quantified using the Quantifiler® Human DNA investigation kit (ThermoFisher Scientific, 
Massachusetts, United States) according to the standard suggested protocol. 
2.4. Bisulfite Conversion 
DNA samples were treated with sodium bisulfite, which converts unmethylated cytosines into 
uracil, while the methylated ones remain unchanged. In this study, the EZ DNA methylation™ 
kit (ZymoResearch, Irvine, United States) was used. For the purpose of this study and 
depending on the experiment, 1-100ng or 10µl of each DNA sample were converted using 
the conversion conditions suggested by the manufacturer. Bisulfite treated DNA samples 
were eluted in 10-20µl of elution buffer and were stored at -20oC for up to one month. 
Together with the samples, pre-defined DNA methylation controls (0-100%) (EpigenDx, 
Hopkinton, United States) were also used in order to assess both bisulfite conversion 
efficiency and the linearity of methylation quantification. 
2.5.  Bisulfite PCR assay 
This assay was designed to specifically amplify bisulfite-treated DNA using the BiSearch 
online tool (http://bisearch.enzim.hu/), which is able to address common issues seen in 
bisulfite PCR such as low efficiency, mis-priming or non-specific amplification. The EFS 
assay includes a PCR primer set (the forward and biotin-labelled reverse); details regarding 
primer sequences and PCR product length are shown in Table 1. Due to location and assay 
design restrictions, only 10 out of the reported 11 CpG sites were investigated. Briefly, each 
PCR reaction consisted of 12.5µl of ZymoTaq PreMix (ZymoResearch), 1µl of 25mM MgCl2 
for a final concentration of 2.75mM (since the ZymoTaq™ Premix also contains 1.75mM 
MgCl2), 1µl of each PCR primer (for a final concentration of 0.4µM), 1µl of bisulfite DNA 
template and 8.5µl of nuclease-free water, for a total reaction volume of 25µl. The 
thermocycling program used was: 95oC for 10 minutes, followed by 45 cycles of 94oC for 30 
seconds, 50oC for 40 seconds, 72oC for 40 seconds, and a final extension step of 72oC for 
15 minutes. Following amplification, the quality of PCR products was assessed on a 2% 
agarose gel. 
Table 1. Designed bisulfite PCR assay 
*The reverse primer is biotin-labelled at its 5’-end. 
 Assay CpGs Primer Sequence (5’  3’) Length (bp) %GC Converted Cs PCR Product (bp) 
EFS 10 
F GGTTTTTTTTTTATTAGTTT 
20 15.0 
9 
195 
R* CTTCATATTATCACTAAAACC 
21 28.6 
5 
 
2.6. Pyrosequencing analysis 
PCR products were converted to single-stranded via biotin-streptavidin selective binding: 
15µl of biotin-labelled PCR products were mixed with 3µl of Streptavidin Sepharose High 
Performance Beads (GE Healthcare, Illinois, United States), 37µl of PyroMark Binding Buffer 
(QIAGEN) as well as 25µl of distilled water for a total volume of 80µl. The solutions were 
then vortexed at 1,000rpm for 30-40 minutes using a clear non-skirted 96-well plate to allow 
for efficient binding of the PCR products to the beads. Afterwards, the beads were isolated 
and captured utilising a Vacuum Prep Workstation (QIAGEN) according to the 
manufacturer’s recommendations. Sequencing reactions were performed by mixing the 
single-stranded templates with 11µl of PyroMark Annealing buffer (QIAGEN) and 1µl of the 
appropriate 10µM sequencing primer. In order to accommodate all 10 CpG sites, two 
primers were used: sequencing primer 1 - TTGTTTTTTTTATGGGAGGG (5’3’) analysing 
the chromosomal region Chr14: 23,835,857-91 (GrCh37/hg19) and sequencing primer 2 – 
GGTTTTTAGTAGAGTTTTTTTA (5’3’) analysing the adjacent region Chr14: 23,835,902-
51. To ensure complete denaturation of DNA templates, these were heated at 80oC for 3 
minutes. Reactions were left at room temperature for 5 minutes in order for the sequencing 
primer to bind before loading them on a PyroMark MD Pyrosequencer (QIAGEN). All four 
nucleotides together with the enzymes and substrates (PyroMark Gold Q96 reagents, 
QIAGEN) were placed into the instrument before analysis following the manufacturer’s 
instructions. 
 
2.7.  Data analysis 
Only pyrograms™ passing the instrument’s quality control were used for analysis; this 
included the detection of desired peaks (no signals in dead injections) as well as detected 
bisulfite conversion rates of >95%. Bisulfite conversion rates were calculated using the peak 
heights of the C/T signals from built-in, non-CpG cytosines in the sequence. Similarly, for 
each CpG site the degree of methylation was measured as a frequency of C/T signals in the 
form of peak heights by the dedicated CpG methylation software, PyroMark CpG SW 1.0 
(QIAGEN). DNA standards of known methylation levels (0%-100%) were used to assess the 
linearity of methylation quantification; the observed methylation ratio was plotted against the 
expected and the best-fitted regression line (linear) was chosen. Furthermore, to assess the 
reproducibility of quantification of the proposed pyrosequencing® assay, 20 blood samples 
were bisulfite-treated and amplified in triplicate using the EFS assay. For this experiment, 
only 10ng of DNA were used (instead of 100ng used in the specificity experiment) to mimic 
more the amounts obtained from forensic-type blood stains and to assess the method’s 
reproducibility in sub-optimal conditions. The mean and standard deviation of the observed 
methylation values were calculated for each sample and for each CpG site. Detected 
methylation data distribution was visualised by employing box-and-whisker plots. Student t-
tests (assuming equal variance of DNA methylation amongst body fluids/tissues) were 
applied to assess whether tissue-specific DNA methylation patterns differ in a statistical 
significant way. This analysis was performed by comparing the levels of DNA methylation 
between body fluids/tissues for each CpG site. For data analysis, the IBM SPSS software 
(v.22, New York, United States) was employed. 
 
3. Results 
3.1.  Accuracy and linearity of methylation quantification 
Non-linear methylation quantification is common in DNA methylation studies, often due to 
potential different amplification efficiencies of the unmethylated and methylated allele during 
PCR [29, 30]. It has been previously suggested that careful primer design and extensive 
optimisation of the PCR step in terms of annealing temperature and MgCl2 concentration might 
be sufficient to correct for this amplification bias [31, 32]. Here, following the optimisation of 
the EFS bisulfite pyrosequencing assay 100ng of each DNA methylation control (0-100%) 
were analysed in duplicate to assess its accuracy and linearity. For this purpose, the mean 
and standard deviation of every control and for each CpG site was calculated. The average 
standard deviation obtained from the duplicated samples was 0.05; however it was much 
higher in certain individual CpG sites, such as CpG 8, and in the 0.75 methylation control. 
Although a standard deviation of 0.05 could be considered as an acceptable degree of 
variability, a methylation difference of 0.26 for the same CpG site of the same sample was 
considered quite high and it is thought that this could be due to events during amplification. In 
general, large differences between CpG sites were sometimes observed, especially in the 
case of the highly methylated control, which resulted in a range of 0.43 - 0.92 detected 
methylation [Figure 1a]. According to the manufacturer, this particular control demonstrates a 
genome-wide >0.85 methylation; however, variations in individual CpG sites cannot be 
excluded and can explain this wide range. Therefore to build the standard curve of methylation 
quantification, the expected methylation values were ‘normalised’ using the values obtained 
for the non-methylated and methylated controls [Figure 1b]. 
 
 
(b) 
<InlineShape1> 
(a) 
<InlineShape2> 
(a) Box plot showing the minimum, first quartile, median, third quartile and maximum 
methylation levels detected for each methylation standard taking into account all ten CpG 
sites, (b) Standard curve showing the observed vs. expected methylation ratio of the 
average methylation per standard after normalisation. Error bars correspond to standard 
deviation. 
 
3.2. Tissue-specific EFS methylation 
As mentioned above, Neumann et al [28] detected differential methylation patterns of the 
EFS gene when analysing various human tissues including the forensically relevant tissues: 
blood (“full” methylation), sperm (“no” methylation) and buccal cells (“partial” methylation). In 
order to apply EFS differential methylation patterns for the detection of whole blood in a 
forensics, various forensically relevant tissues also needed to be investigated; therefore, a 
total of 77 body fluid samples (20 blood, 10 semen, 16 saliva, 10 buccal, 10 vaginal fluid and 
11 menstrual blood samples) were analysed. DNA samples were extracted and quantified; 
the mean (standard deviation) DNA yield per µl of starting material in liquid samples was as 
follows: 17 (7) ng for blood, 62 (56) ng for semen and 14 (31) ng for saliva. In relation to 
material collected on swabs, a buccal swab yielded an average of 2,802 (1,615) ng while a 
vaginal or menstrual secretion swab generated 2,247 (1,542) ng and 2,657 (2,487) ng of 
DNA respectively.  
 
For each sample, 100ng of DNA was bisulfite-treated and amplified using the proposed EFS 
PCR assay. All pyrograms™ passed the quality control of the instrument (expected sequence 
pattern, peak height >70 relative light units, rlu) and the average bisulfite conversion rate of 
the eight built-in conversion controls (non-CpG cytosines included in the sequence) was 94 
± 5%. In general, it was noticed that the obtained individual conversion rates decreased only 
slightly as the sequencing reaction progressed, possibly due to technical reasons (previously 
unincorporated cytosines); however, overall the measured bisulfite conversion rates were 
satisfactory and in agreement with what the manufacturer suggests. 
 
In this analysis and for each CpG site included in the EFS assay we considered two aspects: 
(1) the distribution of DNA methylation levels within a tissue, and (2) the difference of DNA 
methylation levels between different tissues and for each CpG site. While we consider that 
the DNA methylation distribution should be as small as possible to indicate reproducible and 
robust DNA methylation profiles, the difference between tissues should be as large as 
possible to allow for accurate tissue identification. Firstly, to assess these aspects box-and-
whisker plots were drawn for each CpG site and body fluid/tissue [Figure 2]. As shown in 
Figure 2, the average methylation proportion in blood was the highest amongst the body 
fluids examined (0.67 ± 0.16), while semen was found to be almost completely unmethylated 
(0.06 ± 0.04) in all samples, with the exception of two samples, where the mean methylation 
was 0.67 and 0.54 respectively (shown as outliers – outside the range ‘mean±standard 
deviation’) [Figure 2b]. It is believed that this could be due to either natural inter-variability in 
methylation levels or possible presence of blood in semen. The remaining tested tissues 
demonstrated partial methylation levels (saliva - 0.43 ± 0.12, buccal cells - 0.26 ± 0.1, 
vaginal fluid - 0.22 ± 0.07 and menstrual blood - 0.22 ± 0.05) [Figure 2c-f]. Interestingly, 
there were also two samples of menstrual blood that showed a slightly higher methylation 
level (5-15%) for a subset of the investigated CpG sites, which we believe could be due to 
natural inter-individual variation or the effect of the day of the menstrual cycle that the 
samples were collected. Furthermore, the presence of circulatory blood in menstrual blood 
as a result of trauma of some kind cannot be excluded. Overall, there was an inter-individual 
methylation range of 0.33 ± 0.1 when taking into account all samples at each CpG site, with 
saliva showing the highest mean range of 0.5. This range corresponds to the observed inter-
individual variability; therefore the lower it is the more robust the proposed CpG site is 
considered.  
 
Boxes represent the first and third quartile while the horizontal line represents the median 
value. Error bars correspond to the minimum and maximum detected methylation value. 
Outliers are shown as red ‘x’ dots. 
  
Moreover, we aimed to ‘translate’ these differences in DNA methylation levels into 
statistically significant differences that can be used for tissue identification. For this reason, 
we performed independent two-sample t-tests (considering unequal sample sizes but equal 
DNA methylation variance) by comparing the results between all body fluids and tissues 
[Supplementary Table S1]. Despite the large inter-individual variability in certain 
CpGs/tissues or the small DNA methylation differences of certain CpGs between some 
tissues, the results of this statistical analysis are promising. When comparing the DNA 
methylation results of blood with all other tissues, a highly significant difference is observed 
for all CpG sites (p<0.001) [Table S1]. Also, the same is observed when comparing the very 
low methylation profiles of semen samples with the other tissues (despite the two outliers). 
However, the differences are not so clear and significant when tissues of epithelial origin are 
compared. For example, while saliva samples show significantly different DNA methylation 
profiles in comparison to buccal, vaginal and menstrual blood cells, the same cannot be 
concluded when comparing the latter with each other [Table S1]. We believe that these 
results are in agreement with these tissues’ cell type composition, and can also be seen in 
Figure 2 as most samples demonstrate low to intermediate DNA methylation levels for all 
tested CpGs (<0.5).  
 
Considering each CpG site separately, it was observed that CpG 4 seemed to be more 
promising as a blood-specific marker. This is due to the fact that this CpG site not only 
shows the greatest methylation difference between blood (>0.8) and the rest of the tissues 
(<0.8) (with the exception of the two semen outliers), but also the strongest average p-value 
when taking into account all blood to non-blood tissue comparisons (p=3.88E-11). 
Considering the limitations of existing methods including low sensitivity and specificity in 
some instances, a DNA methylation-based approach for the identification of blood using the 
proposed marker (together with others from the literature) can be very beneficial either as a 
complementary method or as a stand-alone assay (and particularly in cases where only 
DNA is available). However, caution is needed when analysing saliva or other body fluids 
that can contain leucocytes, as this could result in obtaining ‘altered’ DNA methylation 
values [33]. 
 
3.3. Inter-individual variability of EFS methylation 
To further test potential inter-individual variability of EFS methylation in blood, an 
independent cohort of blood samples was analysed. To account for possible age-, ethnicity- 
and gender-associated effects, this set included a total of 47 blood samples from female and 
male individuals aged 20-70 years from different ethnic backgrounds [Supplementary Figure 
S1a-b]. The same experimental conditions employed in the specificity experiment were used 
(100ng DNA) and only the first four CpG sites were analysed using the sequencing primer 1. 
The previously obtained levels in blood [Figure 2] were confirmed in this experiment, with no 
significant methylation differences and no outliers in blood. As shown in Figure S1c, CpG 4 
was again confirmed to be the most useful marker since it not only demonstrates the highest 
level of methylation in blood (>0.8) but also the lowest variability; the median (horizontal line) 
is close to 1 (0.98). In contrast, CpG 1 demonstrated a large variation amongst the blood 
samples (0.2 - 0.9), which does not support its use as a blood-specific marker. Lastly, there 
was no significant correlation between methylation and age, ethnicity or gender (p>0.05). 
 
3.4.  Applicability to forensic casework 
It is essential that the observed methylation status of the EFS gene when analysing freshly 
collected body fluids is also detected in samples that are of low quality and/or quantity. To 
assess the stability of EFS methylation as well as its applicability as a blood-specific marker 
in forensic casework, a set of mock casework samples were prepared and analysed. One of 
the most significant advantages of applying DNA methylation profiling for the identification of 
tissues is its potential applicability in cold cases. In most of these cases, forensic tissue 
typing using mRNA profiling cannot be employed either because in stored stains mRNA 
molecules significantly degrade over time or because minute samples or only DNA samples 
are kept (although we understand that this depends on the case circumstances and 
extraction method used). To assess the stability of EFS methylation, a total of five blood 
stains stored at room temperature protected from light for 9-18 years as well as five blood 
DNA samples stored at -20oC for 1-9 years were analysed. In all cases, the expected 
methylation ratios for the investigated CpG sites were obtained (CpG 1 – 0.72 ± 0.05, CpG 2 
– 0.63 ± 0.05, CpG 3 – 0.72 ± 0.05 and CpG 4 – 0.94 ± 0.08), highlighting the stability of 
DNA methylation at these sites.  
 
Furthermore, depending on case circumstances, forensic specimens could be mixed or 
degraded due to exposure to sunlight, high temperature and adverse weather conditions. In 
an attempt to recreate ‘forensic-like’ scenarios, various stains were prepared as described in 
the methods section and their methylation level in the first four EFS CpG sites was 
quantified. The whole swab or stain was used for DNA extraction and eluted in 10µl; then, 
the entire solution of extracted DNA was used for bisulfite treatment and converted DNA was 
also eluted in 10µl. Briefly, all stains stored at various temperatures for a week yielded the 
‘expected’ blood methylation pattern indicating that under these conditions the methylation of 
EFS gene is stable (for example, we obtained >0.90 methylation for all samples stored at -
20oC, 4oC, 25oC, 37oC and outdoors). This is very important as crime stains are often 
exposed to sunlight, so it is encouraging for DNA methylation-based applications to be able 
to prove that methyl groups are stable under these temperatures. On the other hand, 
considering the artificially UV-degraded samples, the ‘expected’ methylation pattern was 
observed for all bloodstains incubated under UV for up to 90 minutes (no statistically 
significant difference compared to the non-UV-treated sample, p>0.05). However, the stain 
that was UV-degraded for 120 minutes resulted in a completely non-methylated profile. This 
could indicate that the methylation levels could have been altered due to the UV light. 
Potential stochastic effects cannot also be excluded, as it is known to be common in highly 
degraded stains. In fact, a likely explanation is that methylated cytosine were deaminated 
following the UV exposure, which were then converted to thymines, hence showing as 
unmethylated sites. This effect of specific intensities and wavelengths of UV light on DNA 
methylation patterns could be further explored in the future. Finally, the stain that was 
incubated for 4 hours under UV light was too degraded to produce an amplicon 
(‘unsuccessful’ STR profiling of this sample also confirmed the extent of its degradation, data 
not shown). 
 
Additionally, although bloodstains on the towel and tissue paper gave successful 
pyrograms™, the methylation obtained from the washed bloodstain was very low (0.08). The 
stained shirt was washed in a public washing machine; therefore potential ‘contamination’ 
with other body fluids/tissues or the effect of chemical reagents could explain this result. 
These factors should be taken into account when interpreting methylation profiles from crime 
scene stains. Also, a reduced methylation was obtained from the stain on the denim jeans 
(average of 0.33), which, in this case, could be due to the effect of dyes on the analysis. As 
all these samples were generally of low-quantity/quality DNA, we cannot exclude that a 
lower DNA template input could partially explain the occasionally observed lower DNA 
methylation levels. Nevertheless, all pyrograms™ passed the built-in quality controls in terms 
of bisulfite conversion and peak quality, however, the peak heights were generally just 
above the threshold of 70rlu. 
 
Lastly, blood, semen and saliva were used to generate two mixed stains; the obtained 
methylation values of both single-source and mixed stains using CpG 4 are presented in 
Figure 3. The potential difficulty of mixture analysis is considered one of the main drawbacks 
of DNA methylation-based tissue identification due its quantitative (value) rather than 
qualitative (peaks) nature. Hence, if applicable in the future, it should be used in combination 
with presumptive testing (if sufficient casework stain is available), mRNA profiling (if mRNA 
is available) and also, DNA profiling, to initially assess the number of potential contributors. It 
was, therefore, important to assess how this assay performed when analysing mixed stains. 
As illustrated, using the observed methylation of single-source tissues, the ‘expected’ 
methylation value was calculated. Although in both cases the observed methylation ratio 
was not significantly different from the ‘expected’ value, correction via the equation of the 
linear regression line in the standard curve for CpG 4 [Figure 3b] improved the accuracy of 
the results. These results are very encouraging; however, the analysis of more mixed stains 
generated in various ratios is necessary before making conclusions about its reliability in 
body-fluid mixtures. 
(b) 
<InlineShape3> 
(a) 
<InlineShape4> 
 
Samples CpG 4 
Blood Observed 0.97 
Semen Observed 0.00 
Saliva Observed 0.51 
Blood:Semen (1:1) Expected 0.49 
Observed 0.61 
Corrected 0.53 
Blood:Saliva (2:1) Expected 0.82 
Observed 0.91 
Corrected  0.84 
 
(a) Observed methylation for all individual and mixed samples. Individual methylation values 
were used to calculate the expected values for the mixed stains. (b) Standard curve for EFS 
CpG 4 showing the observed vs. expected methylation ratios of pre-defined DNA 
methylation controls. The equation of the fitted linear regression line was used to ‘correct’ 
the observed methylation for mixed stains. 
 
4. Discussion 
Neumann et al [28] detected differential methylation patterns of the EFS gene when 
analysing various human tissues including blood, sperm and buccal cells. It is known that 
EFS encodes for a protein playing a role in coordinating cell adhesion via tyrosine-kinase-
based signalling. EFS has been recognised to be a member of the CRISPR-associated 
(CAS) protein family but little is known regarding its function. It has been shown to contain a 
Src homology 3 (SH3) domain and has already been shown to interact with Src-family 
kinases in mice [34]. Research has also suggested that it is an adapter protein that is 
regulated via phosphorylation but has no enzymatic activity [35]. Additionally, its methylation 
mechanism indicates EFS involvement in the differentiation of the hematopoietic cell lineage 
(T-lymphocyte regulation).  Although it has not been linked to cancer to date, other members 
of the CAS family are known oncogenes acting as prognostic markers of metastasis [36]. 
 
The reported blood-specific region of the EFS gene consisting of ten CpG sites was further 
investigated using various forensically relevant tissues and its potential for blood 
identification was confirmed through the detection of the previously reported high 
methylation levels in this tissue. While buccal samples gave a lower methylation range than 
saliva, the latter produced a wider range among individuals, which could be potentially be 
supported by the presence of leukocytes in saliva due to either immunological conditions or 
to gum bleeding. Additionally, it should be noted that while in semen the investigated sites 
were completely unmethylated (<0.2), in 20% of the analysed samples we obtained much 
higher levels for all CpG sites at the investigated EFS locus (0.3-0.8 more methylation 
depending on the CpG site) [Figure 2b]. This could once again be supported by the 
presence of leukocytes in semen, which is not uncommon and it could be attributable to 
various reasons such as sexually transmitted infections or indicate an unknown pathological 
condition [21, 37]. Interestingly, these two semen samples in particular, have also previously 
resulted in ‘odd’ DNA methylation results for other tested genomic loci [38], perhaps 
indicating a wider, ‘abnormal’ DNA methylation profile. To further assess the frequency of 
these outliers, it is necessary that a greater number of semen and other samples need to be 
explored in future studies. These observations and the possibility of observing natural inter-
individual methylation variation among individuals should be taken into account during 
interpretation via a suitable statistical approach.  
 
Nevertheless, one of the analysed CpG sites (CpG 4) was found to be the most useful 
marker for the identification of blood as it demonstrated the highest average methylation 
difference (at least >0.3) between blood and other body fluids. Ideally, in order to be able to 
report with very high certainty that a particular tissue in present, the desired difference of a 
tissue compared to others should display an ‘on-off’ methylation; however this is not always 
possible because of the complexity of tissue constituents. Given that the mean difference in 
methylation between blood and menstrual blood in some previously proposed tissue-specific 
sites is rather low (for example in markers cg03363565 – 0.19 and cg09696411 – 0.33 [12], 
cg06379435 – 0.33 and cg01543184 – 0.30 [25]), the mean detected methylation difference 
for CpG4 in this assay between blood (0.94) and menstrual blood (0.25) should not be 
overlooked as a potential discriminating marker. 
 
Additionally, the assay successfully passed an initial validation phase showing not only that 
methylation levels among a total of 65 blood samples were consistent but also that such an 
assay can be applied in aged stains (up to 18 years at room temperature and protected from 
light), stains stored at a wide range of different temperatures (ranging from -20oC to 37oC for 
up to a week) and degraded samples (up to 90 minutes under UV). However, further 
research is needed to establish the effect of clothing dyes, washing detergents and 
substrates. Moreover, although pyrosequencing® has been proposed as a method that 
produces accurate results, the increased number of PCR cycles (45 cycles) as well as the 
sequencing reaction itself could result in stochastic events and therefore, jeopardise its 
reproducibility. In our case, the mean standard deviation for CpGs 1, 2 and 3 was 0.08, while 
an average standard deviation of 0.05 was obtained for CpG 4 [Figure S1d]. We also believe 
that replicate analysis can be very useful and improve the robustness of observed DNA 
methylation levels, since, in some cases, the observed standard deviation per sample was 
as high as 0.26 (CpG 3). 
 
In an attempt to re-create common environmental conditions often faced in forensic 
casework, such as washed clothes, stains exposed to heat and UV or aged samples, we 
analysed various stains, which most gave the expected EFS methylation profile. This 
indicates that the proposed marker is not only highly blood-specific and robust, but also 
sensitive and stable over time, characteristics that are highly important in such analysis. 
Also, as demonstrated here, it is important not to underestimate the potential of epigenetic 
markers in mixed stains, however more tissue-specific CpG sites should be included for 
each tissue for conclusive results. In complex tissue identification cases, it would perhaps be 
advantageous for one to combine all available approaches, such as tissue-specific mRNA 
profiling. Especially in the case of differentiating blood and menstrual blood, mRNA typing 
has been useful for the inclusion of menstrual blood through the presence of the 
corresponding menstrual blood-specific peaks, but there is always a possibility that the 
presence of non-menstrual blood masks these. DNA methylation profiling could then act as 
a very useful alternative to exclude the presence of non-menstrual blood in situations where 
a non-blood methylation profile is obtained (methylation levels of <0.80 in the case of EFS 
CpG4 suggested in this study). Differences in DNA methylation levels between whole blood 
and menstrual blood are, to some extent, expected to occur, since apart from white blood 
cells menstrual blood swabs usually also contain other cell types, such as vaginal cells and 
skin. 
 
Lastly, future work could include not only an extensive validation of the blood-specific marker 
found in this study, including sensitivity analysis and assessment of its performance 
combined with short tandem repeat (STR) profiling, but also the investigation of the entire 
EFS locus or its promoter, which could reveal more potentially useful CpG sites. Even 
though the proposed CpG 4 showed great robustness in its methylation levels after 
analysing 65 blood samples, to account for potential, common inter-individual differences in 
DNA methylation and consequently, gene expression, a larger dataset of body fluids and 
tissues should be analysed. It would be interesting to also include nasal blood in the 
analysis, which has not been investigated in any similar study before. As nasal blood is often 
recovered in physical assault cases, it would be beneficial to see if the EFS assay would still 
be able to differentiate venous and capillary blood. Additionally, since investigators’ 
questions are often more complex and involve whether it is possible to determine what body 
fluids and tissues are the source of complex mixed DNA profiles obtained in a forensic case, 
such as samples resulted from a head shot or sexual assault samples, it is important to 
further investigate the proposed markers’ usefulness by testing more types of tissues and 
mock casework scenarios.  
 
Furthermore, given the suspected involvement of EFS gene in disease as a member of the 
CAS protein family, analysing diseased tissues of both blood (cancer) and uterus would 
explore the impact on DNA methylation levels. Using a similar approach, investigating other 
genes that demonstrate tissue-specific gene expression (the epigenetic profile), such as the 
haemoglobin gene, could reveal more markers of interest that could then be selected during 
the discovery phase for assay development. A more gene-oriented targeted approach, 
looking at methylation sites potentially involved in gene regulation, could result in markers 
showing ‘stronger’ differences. 
 
5. Conclusion 
In summary, in this study we proposed a novel blood-specific differentially methylated gene 
locus, namely embryonal Fyn-associated substrate (EFS) gene that could act as a good 
candidate marker to confirm the presence of blood as part of a future DNA methylation-
based multiplex tool, which also demonstrated its potential applicability in casework samples 
of questioned quantity and/or quality. In particular, CpG 4 in the EFS assay showed great 
robustness with low inter-individual variation and has potential as an excellent marker to 
assist in the differentiation between whole and menstrual blood. Further research into 
validating such an assay, but also into including additional adjacent CpGs, would shed more 
light into the usefulness of this locus. 
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Figure 1. Linearity of methylation quantification in the EFS assay 
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<InlineImage2> 
Figure 2. Box-and-whisker plots showing the detected methylation levels in (a) blood 
(n=20), (b) semen (n=10), (c) saliva (n=16), (d) buccal cells (n=10), (e) vaginal fluid 
(n=10), (f) menstrual blood (n=11) for all ten CpG sites included in the EFS assay (total 
n=77) 
 
<InlineImage3> 
Figure 3. Methylation analysis of EFS CpG 4 in mixed stains 
 
y = 0.9842x + 0.0842
R² = 0.9535
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.2 0.4 0.6 0.8 1
O
b
s
e
rv
e
d
 m
e
th
y
la
ti
o
n
 r
a
ti
o
Expected methylation ratio
EFS CpG 4
